<DOC>
	<DOCNO>NCT02486809</DOCNO>
	<brief_summary>This study assess bioequivalence healthy participant high-concentration formulation lebrikizumab withdraw vial administer SC single injection needle syringe , low-concentration formulation lebrikizumab administer SC single injection via PFS-NSD .</brief_summary>
	<brief_title>A Bioequivalence Study Subcutaneous ( SC ) Lebrikizumab Administered Needle Syringe Prefilled Syringe With Needle Safety Device ( PFS-NSD )</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Healthy adult 18 65 year age , inclusive Body mass index ( BMI ) 18 32 kg/m^2 body weight 50 100 kg , inclusive Nonpregnant nonlactating female Agreement utilize effective contraception among men woman childbearing potential Known allergy hypersensitivity study drug component History alcohol drug abuse within 12 month prior study drug , positive test alcohol drug abuse Receipt investigational agent within 30 day 5 halflives prior Day 1 Biological therapy within 90 day prior Day 1 Parasitic Listeria monocytogenes infection within 6 month prior Screening Receipt blood product within 2 month prior study entry Donation loss blood/plasma within 6 month prior study drug , depend upon volume Receipt live attenuate vaccine within 1 month prior study drug Use tobacco nicotinecontaining product within 14 day prior Screening Use prescription nonprescription medication within 14 day prior study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>